PLoS ONE (Jan 2022)

Assessment of the percentage of full recombinant adeno-associated virus particles in a gene therapy drug using CryoTEM

  • Mathieu Colomb-Delsuc,
  • Roman Raim,
  • Christian Fiedler,
  • Stefan Reuberger,
  • Johannes Lengler,
  • Rickard Nordström,
  • Martin Ryner,
  • Ioana Mihaela Folea,
  • Barbara Kraus,
  • Juan A. Hernandez Bort,
  • Ida-Maria Sintorn

Journal volume & issue
Vol. 17, no. 6

Abstract

Read online

In spite of continuous development of gene therapy vectors with thousands of drug candidates in clinical drug trials there are only a small number approved on the market today stressing the need to have characterization methods to assist in the validation of the drug development process. The level of packaging of the vector capsids appears to play a critical role in immunogenicity, hence an objective quantitative method assessing the content of particles containing a genome is an essential quality measurement. As transmission electron microscopy (TEM) allows direct visualization of the particles present in a specimen, it naturally seems as the most intuitive method of choice for characterizing recombinant adeno-associated virus (rAAV) particle packaging. Negative stain TEM (nsTEM) is an established characterization method for analysing the packaging of viral vectors. It has however shown limitations in terms of reliability. To overcome this drawback, we propose an analytical method based on CryoTEM that unambiguously and robustly determines the percentage of filled particles in an rAAV sample. In addition, we show that at a fixed number of vector particles the portion of filled particles correlates well with the potency of the drug. The method has been validated according to the ICH Q2 (R1) guidelines and the components investigated during the validation are presented in this study. The reliability of nsTEM as a method for the assessment of filled particles is also investigated along with a discussion about the origin of the observed variability of this method.